Efficacy and safety of zonisamide: results of a multicenter study

I. E. Leppik; L. J. Willmore; R. W. Homan; G. Fromm; K. J. Oommen; J. K. Penry; J. C. Sackellares; D. B. Smith; R. P. Lesser; J. D. Wallace; J. L. Trudeau; L. K. Lamoreaux; M. Spenser

doi:10.1016/0920-1211(93)90021-X

Efficacy and safety of zonisamide: results of a multicenter study

I. E. Leppik, L. J. Willmore, R. W. Homan, G. Fromm, K. J. Oommen, J. K. Penry, J. C. Sackellares, D. B. Smith, R. P. Lesser, J. D. Wallace, J. L. Trudeau, L. K. Lamoreaux, M. Spenser

Experimental and Clinical Pharmacology

Research output: Contribution to journal › Article › peer-review

151 Scopus citations

Abstract

The safety and efficacy of zonisamide (ZNS), a new antiepileptic drug, was tested in 167 adult participants who entered a historical-controlled 16-week open label, multicenter study. The median percent reduction from baseline of partial seizures was 51.8% in the fourth month of the study (baseline median = 11.5 sz/month; treatment weeks 13-16 = 5.5 sz/month). Persons completing the efficacy study successfully were eligible for a long-term safety study; 113 entered this study. Adverse effects involved principally the CNS and were similar to those seen with other antiepileptic drugs. Four persons (3.7%) developed kidney stones and were withdrawn from the study 250-477 days after starting ZNS. Because of the high percentage of kidney stones, development of ZNS was stopped in the United States but was continued in Japan.

Original language	English (US)
Pages (from-to)	165-173
Number of pages	9
Journal	Epilepsy Research
Volume	14
Issue number	2
DOIs	https://doi.org/10.1016/0920-1211(93)90021-X
State	Published - Feb 1993

Keywords

(Epilepsy)
Efficacy
Partial seizures
Safety
Zonisamide

Access

10.1016/0920-1211(93)90021-X

OpenUrl availability

Full text

Cite this

@article{9afc80a5b960409aaff49e15bd8a329a,

title = "Efficacy and safety of zonisamide: results of a multicenter study",

abstract = "The safety and efficacy of zonisamide (ZNS), a new antiepileptic drug, was tested in 167 adult participants who entered a historical-controlled 16-week open label, multicenter study. The median percent reduction from baseline of partial seizures was 51.8% in the fourth month of the study (baseline median = 11.5 sz/month; treatment weeks 13-16 = 5.5 sz/month). Persons completing the efficacy study successfully were eligible for a long-term safety study; 113 entered this study. Adverse effects involved principally the CNS and were similar to those seen with other antiepileptic drugs. Four persons (3.7%) developed kidney stones and were withdrawn from the study 250-477 days after starting ZNS. Because of the high percentage of kidney stones, development of ZNS was stopped in the United States but was continued in Japan.",

keywords = "(Epilepsy), Efficacy, Partial seizures, Safety, Zonisamide",

author = "Leppik, {I. E.} and Willmore, {L. J.} and Homan, {R. W.} and G. Fromm and Oommen, {K. J.} and Penry, {J. K.} and Sackellares, {J. C.} and Smith, {D. B.} and Lesser, {R. P.} and Wallace, {J. D.} and Trudeau, {J. L.} and Lamoreaux, {L. K.} and M. Spenser",

year = "1993",

month = feb,

doi = "10.1016/0920-1211(93)90021-X",

language = "English (US)",

volume = "14",

pages = "165--173",

journal = "Epilepsy Research",

issn = "0920-1211",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Efficacy and safety of zonisamide

T2 - results of a multicenter study

AU - Leppik, I. E.

AU - Willmore, L. J.

AU - Homan, R. W.

AU - Fromm, G.

AU - Oommen, K. J.

AU - Penry, J. K.

AU - Sackellares, J. C.

AU - Smith, D. B.

AU - Lesser, R. P.

AU - Wallace, J. D.

AU - Trudeau, J. L.

AU - Lamoreaux, L. K.

AU - Spenser, M.

PY - 1993/2

Y1 - 1993/2

N2 - The safety and efficacy of zonisamide (ZNS), a new antiepileptic drug, was tested in 167 adult participants who entered a historical-controlled 16-week open label, multicenter study. The median percent reduction from baseline of partial seizures was 51.8% in the fourth month of the study (baseline median = 11.5 sz/month; treatment weeks 13-16 = 5.5 sz/month). Persons completing the efficacy study successfully were eligible for a long-term safety study; 113 entered this study. Adverse effects involved principally the CNS and were similar to those seen with other antiepileptic drugs. Four persons (3.7%) developed kidney stones and were withdrawn from the study 250-477 days after starting ZNS. Because of the high percentage of kidney stones, development of ZNS was stopped in the United States but was continued in Japan.

AB - The safety and efficacy of zonisamide (ZNS), a new antiepileptic drug, was tested in 167 adult participants who entered a historical-controlled 16-week open label, multicenter study. The median percent reduction from baseline of partial seizures was 51.8% in the fourth month of the study (baseline median = 11.5 sz/month; treatment weeks 13-16 = 5.5 sz/month). Persons completing the efficacy study successfully were eligible for a long-term safety study; 113 entered this study. Adverse effects involved principally the CNS and were similar to those seen with other antiepileptic drugs. Four persons (3.7%) developed kidney stones and were withdrawn from the study 250-477 days after starting ZNS. Because of the high percentage of kidney stones, development of ZNS was stopped in the United States but was continued in Japan.

KW - (Epilepsy)

KW - Efficacy

KW - Partial seizures

KW - Safety

KW - Zonisamide

UR - http://www.scopus.com/inward/record.url?scp=0027500338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027500338&partnerID=8YFLogxK

U2 - 10.1016/0920-1211(93)90021-X

DO - 10.1016/0920-1211(93)90021-X

M3 - Article

C2 - 8453952

AN - SCOPUS:0027500338

SN - 0920-1211

VL - 14

SP - 165

EP - 173

JO - Epilepsy Research

JF - Epilepsy Research

IS - 2

ER -

Efficacy and safety of zonisamide: results of a multicenter study

Abstract

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this